IP Library › Granted Patent US 7,060,248

Granted Patent B2

US 7,060,248 · App. 10/645,272 · Granted Jun 13, 2006

Matrix metalloproteinase inhibitors

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,060,248
App. No.: 10/645,272
Granted: Jun 13, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.

Claims (489)

1. A method of detecting, imaging or monitoring congestive heart failure in a patient, comprising the steps of:

administering a diagnostic agent to the patient; and

acquiring an image of a site of concentration of the diagnostic agent in the patient by a diagnostic imaging technique;

wherein the diagnostic agent comprises a diagnostic metal and a compound of the formula:

(Q) d —(L n ) x″ —K

or a pharmaceutically acceptable salt thereof;

wherein

Q is a matrix metalloproteinase inhibitor of formula (Ia) or (Ib):

L n is an optional linking group having the formula:

((W 1 ) h —(CR 13 R 14 ) g ) x —(Z) k —((CR 13a R 14a ) g′ —(W 2 ) h′ ) x′ ;

K is a chelator having a formula selected from the group:

R is independently OH or —CH 2 SH;

R 1 is independently selected at each occurrence from the group: H, OH, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, and heterocycle-S—CH 2 —;

R 2 is independently C 1-20 alkyl;

X is independently C═O or SO 2 , provided when X is C═O, R 3 is

and when X is SO 2 , R 3 is independently selected from the group: aryl substituted with 0-2 R 6 , and heterocycle substituted with 0-2 R 6 ;

R 4 is independently selected at each occurrence from the group: C 1-6 alkyl, phenyl, and benzyl;

R 5 is independently at each occurrence from the group: NH(C 1-6 alkyl), NH-phenyl, and NH-heterocycle; wherein said alkyl, phenyl and heterocycle groups are optionally substituted with a bond to L n or a bond to K;

R 6 is independently aryloxy substituted with 0-3 R 7 ;

R 7 is independently halogen or methoxy; or alternatively,

R 1 and R 4 may be taken together to form a bridging group of the formula —(CH 2 ) 3 —O-phenyl-CH 2 —, optionally substituted with a bond to L n or a bond to K; or alternatively,

R 1 and R 2 may be taken together to form a bridging group of the formula —(CH 2 ) 3 —NH—, optionally substituted with a bond to L n or a bond to K; or

R 1 and R 2 taken together with the nitrogen and carbon atom through which they are attached form a saturated ring system containing 5-7 carbon atoms substituted with one or more substituents selected from the group consisting of: a bond to L n , a bond to K, and —C(═O)—NR 29 R 30 ;

R 8 is independently at each occurrence OH or phenyl, optionally substituted with a bond to L n or a bond to K, provided that when R 8 is phenyl, R 10 is —C(═O)—CR 12 —NH—CH(CH 3 )—COOH;

R 9 and R 9′ are independently H, C 1-6 alkyl optionally substituted with a bond to L n or a bond to K, or are taken together with the carbon atom to which R 9 and R 9′ are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-3 heteroatoms selected from O, N, SO 2 and S, said ring system substituted with R 6 and optionally substituted with a bond to L n or a bond to K;

R 10 and R 11 are independently H, C 1-6 alkyl optionally substituted with a bond to L n or a bond to K, or are taken together with the nitrogen atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing, in addition to the nitrogen atom to which R 10 and R 11 are attached, 0-3 heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with 0-3 R 27 , a bond to L n or a bond to K; or alternatively,

R 9 and R 10 are taken together with the carbon atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing, in addition to the nitrogen atom to which R 10 is attached, 0-3 heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with a bond to L n or a bond to K;

R 12 is independently C 1-20 alkyl;

R 27 is ═O, C 1-4 alkyl, or phenyl substituted with R 28 ;

R 28 is a phenoxy group substituted with 0-2 OCH 3 groups;

R 29 and R 30 taken together with the nitrogen atom through which they are attached form a saturated ring system containing 5-7 carbon atoms substituted with R 31 ;

R 31 is a benzyloxy group substituted with C 1-4 alkyl;

d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

W 1 and W 2 are independently selected at each occurrence from the group: O, S, NH, NHC(═O), C(═O)NH, NR 15 C(═O), C(═O)NR 15 , C(═O), C(═O)O, OC(═O), NHC(═S)NH, NHC(═O)NH, SO 2 , SO 2 NH, —(OCH 2 CH 2 ) 76-84 , (OCH 2 CH 2 ) s , (CH 2 CH 2 O) s′ , (OCH 2 CH 2 CH 2 ) s″ , (CH 2 CH 2 CH 2 O) t , and (aa) t′ ;

aa is independently at each occurrence an amino acid;

Z is selected from the group: aryl substituted with 0-3 R 16 , C 3-10 cycloalkyl substituted with 0-3 R 16 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 16 ;

R 13 , R 13a , R 14 , R 14a , and R 15 are independently selected at each occurrence from the group: H, ═O, COOH, SO 3 H, PO 3 H, C 1-5 alkyl substituted with 0-3 R 16 , aryl substituted with 0-3 R 16 , benzyl substituted with 0-3 R 16 , and C 1-5 alkoxy substituted with 0-3 R 16 , NHC(═O)R 17 , C(═O)NHR 17 , NHC(═O)NHR 17 , NHR 17 , R 17 , and a bond to K;

R 16 is independently selected at each occurrence from the group: a bond to K, COOR 17 , C(═O)NHR 17 , NHC(═O)R 17 , OH, NHR 17 , SO 3 H, PO 3 H, —OPO 3 H 2 , —OSO 3 H, aryl substituted with 0-3 R 17 , C 1-5 alkyl substituted with 0-1 R 18 , C 1-5 alkoxy substituted with 0-1 R 18 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 17 ;

R 17 is independently selected at each occurrence from the group: H, alkyl substituted with 0-1 R 18 , aryl substituted with 0-1 R 18 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R 18 , C 3-10 cycloalkyl substituted with 0-1 R 18 , polyalkylene glycol substituted with 0-1 R 18 , carbohydrate substituted with 0-1 R 18 , cyclodextrin substituted with 0-1 R 18 , amino acid substituted with 0-1 R 18 , polycarboxyalkyl substituted with 0-1 R 18 , polyazaalkyl substituted with 0-1 R 18 , peptide substituted with 0-1 R 18 , wherein the peptide is comprised of 2-10 amino acids, 3,6-O-disulfo-B-D-galactopyranosyl, bis(phosphonomethyl)glycine, and a bond to K;

R 18 is a bond to K;

k is selected from 0, 1, and 2;

h is selected from 0, 1, and 2;

h′ is selected from 0, 1, and 2;

g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

g′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s″ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

t is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

t′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

x is selected from 0, 1, 2, 3, 4, and 5;

x′ is selected from 0, 1, 2, 3, 4, and 5;

x″ is selected from 0 and 1;

A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: N, NR 26 , NR 19 , NR 19 R 20 , S, SH, —S(Pg), O, OH, PR 19 , PR 19 R 20 , —O—P(O)(R 21 )—O—, P(O)R 21 R 22 , a bond to Q and a bond to L n ;

Pg is a thiol protecting group;

E 1 , E 2 , E 3 , E 4 , E 5 , E 6 , E 7 , and E 8 are independently a bond, CH, or a spacer group independently selected at each occurrence from the group: C 1-16 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , C 3-10 cycloalkyl substituted with 0-3 R 23 , heterocyclo-C 1-10 alkyl substituted with 0-3 R 23 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C 6-10 aryl-C 1-10 alkyl substituted with 0-3 R 23 , C 1-10 alkyl-C 6-10 aryl-substituted with 0-3 R 23 , and a 5-10 membered heterocyclic ring system containing 1-4 hetero atoms independently selected from N, S, and O and substituted with 0-3 R 23 ;

R 19 and R 20 are each independently selected from the group: a bond to L n , a bond to Q, hydrogen, C 1-10 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , C 3-10 cycloalkyl substituted with 0-3 R 23 , heterocyclo-C 1-10 alkyl substituted with 0-3 R 23 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C 6-10 aryl-C 1-10 alkyl substituted with 0-3 R 23 , C 1-10 alkyl-C 6-10 aryl-substituted with 0-3 R 23 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 23 , and an electron, provided that when one of R 19 or R 20 is an electron, then the other is also an electron;

R 21 and R 22 are each independently selected from the group: a bond to L n , a bond to Q, —OH, C 1-10 alkyl substituted with 0-3 R 23 , C 1-10 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , C 3-10 cycloalkyl substituted with 0-3 R 23 , heterocyclo-C 1-10 alkyl substituted with 0-3 R 23 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C 6-10 aryl-C 1-10 alkyl substituted with 0-3 R 23 , C 1-10 alkyl-C 6-10 aryl-substituted with 0-3 R 23 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 23 ;

R 23 is independently selected at each occurrence from the group: a bond to L n , a bond to Q, ═O, F, Cl, Br, I, —CF 3 , —CN, —CO 2 R 24 , —C(═O)R 24 , —C(═O)N(R 24 ) 2 , —CHO, —CH 2 OR 24 , —OC(═O)R 24 , —OC(═O)OR 24a , —OR 24 , —OC(═O)N(R 24 ) 2 , —NR 25 C(═O)R 24 , —NR 25 C(═O)OR 24a , —NR 25 C(═O)N(R 24 ) 2 , —NR 25 SO 2 N(R 24 ) 2 , —NR 25 SO 2 R 24a , —SO 3 H, —SO 2 R 24a , —SR 24 , —S(═O)R 24a , —SO 2 N(R 24 ) 2 , —N(R 24 ) 2 , —NHC(═S)NHR 24 , ═NOR 24 , NO 2 , —C(═O)NHOR 24 , —C(═O)NHNR 24 R 24a , —OCH 2 CO 2 H, 2-(1-morpholino)ethoxy, C 1-5 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl, C 2-6 alkoxyalkyl, aryl substituted with 0-2 R 24 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O;

wherein at least one of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 or R 23 is a bond to L n or Q;

R 24 , R 24a , and R 25 are independently selected at each occurrence from the group: a bond to L n , a bond to Q, H, C 1-6 alkyl, phenyl, benzyl, C 3-6 alkoxy, halide, nitro, cyano, and trifluoromethyl; and

R 26 is a co-ordinate bond to a metal or a hydrazine protecting group; or

a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 , wherein:

R is OH;

R 1 is independently selected at each occunence from the group: H, OH, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, and heterocycle-S—CH 2 —;

R 2 is independently C 1-6 alkyl;

X is C═O;

R 4 is independently selected at each occurrence from the group: C 1-6 alkyl, phenyl, and benzyl;

R 8 is OH;

R 9 and R 9′ are independently H, C 1-6 alkyl optionally substituted with a bond to L n or a bond to K, or are taken together with the carbon atom to which R 9 and R 9′ are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-1 heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with a bond to L n or a bond to K;

R 10 and R 11 are independently H, or C 1-6 alkyl optionally substituted with a bond to L n or a bond to K, or are taken together with the nitrogen atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing, in addition to the nitrogen atom to which R 10 and R 11 are attached, 0-1 heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with 0-3 R 27 , a bond to L n , or a bond to K; or alternatively,

R 9 and R 10 are taken together with the carbon atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing, in addition to the nitrogen atom to which R 10 is attached, 0-1 heteroatoms selected from O, N, SO 2 , and S, said ring system optionally substituted with a bond to L n or a bond to K; and

R 12 is independently C 1-6 alkyl.

3. A method according to claim 1 , wherein:

R is —OH;

R 2 is C 1-6 alkyl;

X is C═O;

R 3 is

R 1 and R 4 are taken together to form a bridging group of formula —(CH 2 ) 3 —O-phenyl-CH 2 —; and

R 5 is NR(C 1-6 alkyl), substituted with a bond to L n , or a bond to K.

4. A method according to claim 1 , wherein:

R is —OH;

R 9 is C 1 alkyl substituted with a bond to L n ; and

R 10 and R 11 taken together with the nitrogen atom to which they are attached form a 5 atom saturated ring system, said ring system substituted with 0-3 R 27 .

5. A method according to claim 1 , wherein:

R is —OH; and

6. A method according to claim 1 , wherein:

Z is selected from the group: aryl substituted with 0-1 R 16 , C 3-10 cycloalkyl substituted with 0-1 R 16 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R 16 ;

R 13 , R 13a , R 14 , R 14a , and R 15 are independently selected at each occurrence from the group: H, ═O, COOH, SO 3 H, C 1-5 alkyl substituted with 0-1 R 16 , aryl substituted with 0-1 R 16 , benzyl substituted with 0-1 R 16 , and C 1-5 alkoxy substituted with 0-1 R 16 , NHC(═O)R 17 , C(═O)NHR 17 , NHC(═O)NHR 17 , NHR 17 , R 17 , and a bond to K;

k is 0 or 1;

s is selected from 0, 1, 2, 3, 4, and 5;

s′ is selected from 0, 1, 2, 3, 4, and 5;

s″ is selected from 0, 1, 2, 3, 4, and 5; and

t is selected from 0, 1, 2, 3, 4, and 5.

7. A method according to claim 1 , wherein:

is C(═O)NR 15 ;

h is 1;

g is 3;

R 13 and R 14 are independently H;

x is 1;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

8. A method according to claim 1 , wherein:

x is 0;

k is 1;

Z is aryl substituted with 0-3 R 16 ;

g′ is 1;

W 2 is NH;

R 13a and R 14a are independently H;

h′ is 1; and

x′ is 1.

9. A method according to claim 1 , wherein:

W 1 is C(═O)NR 15 ;

h is 1;

g is 2;

R 13 and R 14 are independently H;

x is 1;

k is 0;

g′ is 1;

R 13a and R 14a are independently H; or C 1-5 alkyl substituted with 0-3 R 16 ;

R 16 is SO 3 H;

W 2 is NHC(═O) or NH;

h′ is 1; and

x′ is 2.

10. A method according to claim 1 , wherein:

W 1 is C(═O)NH;

h is 1;

g is 3;

R 13 and R 14 are independently H;

k is 0;

g′ is 0;

x is 1;

W 2 is —NH(C═O)— or —(OCH 2 CH 2 ) 76-84 —;

h′ is 2; and

x′ is 1.

11. A method according to claim 1 , wherein:

x is 0;

k is 0;

g′ is 3;

h′ is 1;

W 2 is NH; and

x′ is 1.

12. A method according to claim 1 , wherein

x is 0;

Z is aryl substituted with 0-3 R 16 ;

k is 1;

g′ is 1;

R 13a and R 14a are independently H;

W 2 is NHC(═O) or —(OCH 2 CH 2 ) 76-84 —; and

x′ is 1.

13. A method according to claim 1 , wherein:

W 1 is C═O;

g is 2;

R 13 and R 14 are independently H;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

14. A method according to claim 1 , wherein:

h′ is 1;

W 2 is NH; and

x′ is 1.

15. A method according to claim 1 , wherein:

x is 0;

Z is aryl substituted with 0-3 R 16 ;

k is 1;

g′ is 1;

R 13a and R 14a are independently H;

W 2 is NHC(═O) or —(OCH 2 CH 2 ) 76-84 —; and

x′ is 1.

16. A method according to claim 1 , wherein:

W 1 is C═O;

g is 2;

R 13 and R 14 are independently H;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

17. A method according to claim 1 , wherein

A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 19 , NR 19 R 20 , S, SH, OH, a bond to Q and a bond to L n ;

E 1 , E 2 , E 3 , E 4 , E 5 , E 6 , E 7 , and E 8 are independently a bond, CH, or a spacer group independently selected at each occurrence from the group: C 1-10 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , C 3-10 cycloalkyl substituted with 0-3 R 23 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 23 ;

R 19 and R 20 are each independently selected from the group: a bond to Q, a bond to L n , hydrogen, C 1-10 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 23 , and an electron;

R 23 is independently selected at each occurrence from the group: a bond to Q, a bond to L n , ═O, F, Cl, Br, I, —CF 3 , —CN, —CO 2 R 24 , —C(═O)R 24 , —C(═O)N(R 24 ) 2 , —CH 2 OR 24 , —OC(═O)R 24 , —OC(═O)OR 24a , —OR 24 , —OC(═O)N(R 24 ) 2 , —NR 25 C(═O)R 24 , —NR 25 C(═O)OR 24a , —NR 25 C(═O)N(R 24 ) 2 , —NR 25 SO 2 N(R 24 ) 2 , —NR 25 SO 2 R 24a , —SO 3 H, —SO 2 R 24a , —S(═O)R 24a , —SO 2 N(R 24 ) 2 , —N(R 24 ) 2 , —NHC(═S)NHR 24 , ═NOR 24 , —C(═O)NHNR 24 R 24a , —OCH 2 CO 2 H, and 2-(1-morpholino)ethoxy; and

R 24 , R 24a , and R 25 are independently selected at each occurrence from the group: a bond to L n , H, and C 1-6 alkyl.

18. A method according to claim 1 , wherein K is:

A 1 is a bond to L n ;

A 2 , A 4 , and A 6 are each N;

A 3 , A 5 , A 7 and A 8 are each OH;

E 1 , E 2 , and E 4 are C 2 alkyl;

E 3 , E 5 , E 7 , and E 8 are C 2 alkyl substituted with 0-1 R 23 ; and

R 23 is ═O.

19. A method according to claim 1 , wherein K is:

wherein:

A 5 is a bond to Ln;

A 1 , A 3 , A 7 and A 8 are each OH;

A 2 , A 4 and A 6 are each N;

E 1 , E 3 , E 5 , E 7 , and E 8 are C 2 alkyl substituted with 0-1R 23 ;

E 2 and E 4 l are C 2 alkyl; and

R 23 is ═O.

20. A method according to claim 1 , wherein K is:

A 1 , A 2 , A 3 and A 4 are each N;

A 5 , A 6 and A 8 are each OH;

A 7 is a bond to L n ;

E 1 , E 2 , E 3 , E 4 are each independently C 2 alkyl; and

E 5 , E 6 , E 7 , E 8 are each independently C 2 alkyl substituted with 0-1 R 23 ; and

R 23 is ═O.

21. A method according to claim 1 , wherein K is:

A 1 is NR 26 ;

R 26 is a co-ordinate bond to a metal or a hydrazine protecting group;

E 1 is a bond;

A 2 is NHR 19 ;

R 19 is a heterocycle substituted with R 23 , the heterocycle being selected from pyridine and pyrimidine;

R 23 is selected from a bond to L n , C(═O)NHR 24 and C(═O)R 24 ; and

R 24 is a bond to L n .

22. A method according to claim 1 , wherein wherein K is:

wherein:

A 1 and A 5 are each —S(Pg);

E 1 and E 4 are C 2 alkyl substituted with 0-1 R 23 ;

R 23 is ═O;

A 2 and A 4 are each —NH;

E 2 is CH 2 ;

E 3 is C 1-3 alkyl substituted with 0-1 R 23 ; and

A 3 is a bond to Ln.

23. A method according to claim 1 , wherein K is:

wherein:

A 1 is a bond to Ln;

E 1 is C 1 alkyl substituted by R 23 ;

A 2 is NH;

E 2 is C 2 alkyl substituted with 0-1 R 23 ;

A 3 is —O—P(O)(R 21 )—O—;

E 3 is C 1 alkyl;

A 4 and A 5 are each —O—;

E 4 and E 6 are each independently C 1-16 alkyl substituted with 0-1 R 23 ;

E 5 is C 1 alkyl;

R 21 is —OH; and

R 23 is ═O.

24. A method according to claim 1 , wherein the compound is:

2-{[5-(3-{2-[(6-Hydroxycarbamoyl-7-isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-10-carbonyl)-amino]-acetylamino}-propylcarbamoyl)-pyridin-2-yl]-hydrazonomethyl}-benzenesulfonic acid;

2-{[5-(4-{[(6-Hydroxycarbamoyl-7-isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-10-carbonyl)-amino]-methyl}-benzylcarbamoyl)-pyridin-2-yl]-hydrazonomethyl}-benzenesulfonic acid;

2-[7-({N-[3-(2-{[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]carbonylamino}acetylamino)propyl]carbamoyl}methyl)-1,4,7,10-tetraaza-4,10-bis(carboxymethyl)cyclododecyl]acetic acid;

2-{7-[(N-{[4-({[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]-carbonylamino}methyl)phenyl]methyl}carbamoyl)methyl]-1,4,7,10-tetraaza-4,10-bis(carboxymethyl)cyclododecyl}acetic acid;

2-(7-{[N-(1-{N-[3-(2-{[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12 (16),13-trien-3-yl]carbonylamino}acetylamino)propyl]carbamoyl}-2-sulfoethyl)carbamoyl]methyl}-1,4,7,10-tetraaza-4,10-bis(carboxymethyl)cyclododecyl)acetic acid;

2-[7-({N-[1-(N-{[4-({[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]-carbonylamino}methyl)phenyl]methyl}carbamoyl)-2-sulfoethyl]carbamoyl}methyl)-1,4,7,10-tetraaza-4,10-bis(carboxymethyl)cyclododecyl]acetic acid;

2-({2-[({N-[3-(2-{[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]carbonylamino}acetylamino)propyl]carbamoyl}methyl)(carboxymethyl)amino}ethyl){2-[bis(carboxymethyl)amino]ethyl}amino]acetic acid;

2-[(2-{[(N-{[4-({[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]-carbonylamino}methyl)phenyl]methyl}carbamoyl)methyl](carboxymethyl)amino}ethyl){2-[bis(carboxymethyl)amino]ethyl}amino]acetic acid;

N-[3-(2-{[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]carbonylamino}acetylamino)propyl]-4,5-bis[2-(ethoxyethylthio)acetylamino]pentanamide;

N-{[4-({[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]carbonylamino}methyl)-phenyl]methyl}-4,5-bis[2-(ethoxyethylthio)acetylamino]-pentanamide;

1-(1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamino)-α,ω-dicarbonylPEG 3400 -2-{[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]carbonylamino}-N-(3-aminopropyl)acetamide;

1-(1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamino)-α,ω-dicarbonylPEG 3400 -[7-(N-hydroxycarbamoyl)(3S,6R,7S)-4-aza-6-(2-methylpropyl)-11-oxa-5-oxobicyclo[10.2.2]hexadeca-1(15),12(16),13-trien-3-yl]-N-{[4-(aminomethyl)phenyl]methyl}carboxamide conjugate;

2-[2-({5-[N-(5-(N-hydroxycarbamoyl)(5R)-5-{3-[4-(3,4-dimethoxyphenoxy)phenyl]-3-methyl-2-oxopyrrolidinyl}pentyl)carbamoyl](2-pyridyl)}amino)(1Z)-2-azavinyl]benzenesulfonic acid;

2-(2-{[5-(N-{3-[3-(N-hydroxycarbamoyl)(4S)-4-({4-[(4-methylphenyl)methoxy]piperidyl}carbonyl)piperidyl]-3-oxopropyl}carbamoyl)(2-pyridyl)]amino}(1Z)-2-azavinyl)benzenesulfonic acid;

a pharmaceutically acceptable salt thereof.

25. A method according to claim 1 , wherein the compound is:

a pharmaceutically acceptable salt thereof.

26. A method according to claim 1 , wherein the diagnostic metal is selected from the group consisting of: a paramagnetic metal, a ferromagnetic metal, a gamma-emitting radioisotope, positron-emitting radioisotope and an x-ray absorber.

27. A method according to claim 26 , wherein the diagnostic metal is a gamma-emitting radioisotope selected from the group consisting of 99m Tc, 95 Tc, 111 In, 62 Cu, 64 Cu, 67 Ga, and 68 Ga.

28. A method according to claim 27 , further comprising a first ancillary ligand and a second ancillary ligand capable of stabilizing the gamma-emitting radioisotope.

29. A method according to claim 27 , wherein the gamma-emitting radioisotope is 99 m Tc.

30. A method according to claim 27 , wherein the gamma-emitting radioisotope is 111 In.

31. A method according to claim 26 , wherein the paramagnetic metal ion is selected from the group consisting of Gd(III), Dy(III), Fe(III), and Mn(II).

32. A method according to claim 26 , wherein the x-ray absorber is a metal is selected from the group consisting of: Re, Sm, Ho, Lu, Pm, Y, Bi, Pd, Gd, La, Au, Au, Yb, Dy, Cu, Rh, Ag, and Ir.

33. A method of detecting, imaging or monitoring congestive heart failure in a patient, comprising the steps of:

administering a diagnostic agent to the patient; and

acquiring an image of a site of concentration of the diagnostic agent in the patient by a diagnostic imaging technique;

wherein the diagnostic agent comprises an echogenic gas and a compound of the formula:

(Q) d —(L n ) x″ —K

or a pharmaceutically acceptable salt thereof;

wherein

Q is a matrix metalloproteinase inhibitor of formula (Ia) or (Ib):

L n is an optional linking group having the formula:

((W 1 ) h —(CR 13 R 14 ) g ) x —(Z) k —((CR 13a R 14a ) g′ —(W 2 ) h′ ) x′ ;

K is a surfactant capable of forming an echogenic gas filled lipid sphere or microbubble, wherein the surfactant is a lipid or a compound having a formula selected from the group:

R is independently OH or —CH 2 SH;

R 1 is independently selected at each occurrence from the group: H, OH, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, and heterocycle-S—CH 2 —;

R 2 is independently C 1-20 alkyl;

X is independently C═O or SO 2 , provided when X is C═O, R 3 is

and when X is SO 2 , R 3 is independently selected from the group: aryl substituted with 0-2 R 6 , and heterocycle substituted with 0-2 R 6 ;

R 4 is independently selected at each occurrence from the group: C 1-6 alkyl, phenyl, and benzyl;

R 6 is independently aryloxy substituted with 0-3 R 7 ;

R 7 is independently halogen or methoxy; or alternatively,

R 1 and R 4 may be taken together to form a bridging group of the formula —(CH 2 ) 3 —O-phenyl-CH 2 —, optionally substituted with a bond to L n or a bond to K; or alternatively,

R 1 and R 2 may be taken together to form a bridging group of the formula —(CH 2 ) 3 —NH—, optionally substituted with a bond to L n or a bond to K; or

R 8 is independently at each occurrence OH or phenyl, optionally substituted with a bond to L n or a bond to K, provided that when R 8 is phenyl, R 10 is —C(═O)—CR 12 —NH—CH(CH 3 )—COOH;

R 12 is independently C 1-20 alkyl;

R 27 is ═O, C 1-4 alkyl, or phenyl substituted with R 28 ;

R 28 is a phenoxy group substituted with 0-2 OCH 3 groups;

R 29 and R 30 taken together with the nitrogen atom through which they are attached form a saturated ring system containing 5-7 carbon atoms substituted with R 31 ;

R 31 is a benzyloxy group substituted with C 1-4 alkyl;

d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

W 1 and W 2 are independently selected at each occurrence from the group: O, S, NH, NHC(═O), C(═O)NH, NR 15 C(═O), C(═O)NR 15 , C(═O), C(═O)O, OC(═O), NHC(═S)NH, NHC(═O)NH, SO 2 , SO 2 NH, —(OCH 2 CH 2 ) 76-84 , (OCH 2 CH 2 ) S , (CH 2 CH 2 O) s′ , (OCH 2 CH 2 CH 2 ) s″ , (CH 2 CH 2 CH 2 O) t , and (aa) t′ ;

aa is independently at each occurrence an amino acid;

R 18 is a bond to K;

k is selected from 0, 1, and 2;

h is selected from 0, 1, and 2;

h′ is selected from 0, 1, and 2;

g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

g′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

s″ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

t is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

t′ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;

x is selected from 0, 1, 2, 3, 4, and 5;

x′ is selected from 0, 1, 2, 3, 4, and 5;

x″ is selected from 0 and 1;

A 1 , A 2 , A 3 , A 4 , A 5 , and A 6 are independently selected at each occurrence from the group: N, NR 26 , NR 19 , NR 19 R 20 , S, SH, —S(Pg), O, OH, PR 19 , PR 19 R 20 , —O—P(O)(R 21 )—O—, P(O)R 21 R 22 , a bond to Q and a bond to L n ;

A 9 is selected from the group: OH and OR 32 ;

A 10 is OR 32 ;

R 32 is C(═O)C 1-20 alkyl;

Pg is a thiol protecting group;

E 1 , E 2 , E 3 , E 4 , E 5 are independently a bond, CH, or a spacer group independently selected at each occurrence from the group: C 1-16 alkyl substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , C 3-10 cycloalkyl substituted with 0-3 R 23 , heterocyclo-C 1-10 alkyl substituted with 0-3 R 23 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C 6-10 aryl-C 1-10 alkyl substituted with 0-3 R 23 , C 1-10 alkyl-C 6-10 aryl-substituted with 0-3 R 23 , and a 5-10 membered heterocyclic ring system containing 1-4 hetero atoms independently selected from N, S, and O and substituted with 0-3 R 23 ;

E 9 is C 1-10 alkylene substituted with 1-3 R 33 ;

R 33 is independently selected at each occurrence from the group: R 35 , —PO 3 H—R 35 , ═O, —CO 2 R 34 , —C(═O)R 34 , —C(═O)N(R 34 ) 2 , —CH 2 OR 34 , —OR 34 , —N(R 34 ) 2 , C 1-5 alkyl, and C 24 alkenyl;

R 34 is independently selected at each occurrence from the group: R 35 , H, C 1-6 alkyl, phenyl, benzyl, and trifluoromethyl;

R 35 is a bond to L n ;

wherein at least one of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 or R 23 is a bond to L n or Q;

R 24 , R 24a , and R 25 are independently selected at each occurrence from the group: a bond to L n , a bond to Q, H, C 1-6 aIkyl, phenyl, benzyl, C 1-6 alkoxy, halide, nitro, cyano, and trifluoromethyl; and

R 26 is a co-ordinate bond to a metal or a hydrazine protecting group.

34. A method according to claim 33 , wherein:

R is OH;

R 1 is independently selected at each occurrence from the group: H, OH, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, and heterocycle-S—CH 2 —;

R 2 is independently C 1-6 alkyl;

X is C═O;

R 4 is independently selected at each occurrence from the group: C 1-6 alkyl, phenyl, and benzyl;

R 8 is OH;

R 9 and R 9′ are independently H, C 1-6 alkyl optionally substituted with a bond to L n , or a bond to K, or are taken together with the carbon atom to which R 9 and R 9′ are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-1 heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with a bond to L n or a bond to K;

R 9 and R 10 are taken together with the carbon atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing, in addition to the nitrogen atom to which R 10 is attached, 0-1 heteroatoms selected from O, N, SO 2 , and S, said ring system optionally substituted with a bond to L n , or a bond to K;

R 12 is independently C 1-6 alkyl.

35. A method according to claim 33 , wherein:

R is —OH;

R 2 is C 1-6 alkyl;

X is C═O;

R 3 is

R 1 and R 4 are taken together to form a bridging group of formula —(CH 2 ) 3 —O-phenyl-CH 2 —; and

R 5 is NH(C 1-6 alkyl), substituted with a bond to L n , or a bond to K.

36. A method according to claim 33 , wherein:

R is —OH;

R 9 is C 1 alkyl substituted with a bond to L n ; and

R 10 and R 11 taken together with the nitrogen atom to which they are attached form a 5 atom saturated ring system, said ring system substituted with 0-3 R 27 .

37. A method according to claim 33 , wherein:

R is —OH;

R 29 and R 30 taken together with the nitrogen atom through which they are attached form a saturated ring system containing 5-7 carbon atoms substituted with R 31 ; and

R 31 is a benzyloxy group substituted with C 1-4 alkyl.

38. A method according to claim 33 , wherein:

W 1 and W 2 are independently selected at each occurrence from the group: O, NH, NHC(═O), C(═O)NH, NR 15 C(═O), C(═O)NR 15 , C(═O), C(═O)O, OC(═O), NHC(═S)NH, NHC(═O)NH, SO 2 , —(CH 2 CH 2 O) 76-84 —, (OCH 2 CH 2 ) s , (CH 2 CH 2 O) s′ , (OCH 2 CH 2 CH 2 ) s″ , (CH 2 CH 2 CH 2 O) t , and (aa) t′ ;

aa is independently at each occurrence an amino acid;

k is 0 or 1;

s is selected from 0, 1, 2, 3, 4, and 5;

s′ is selected from 0, 1, 2, 3, 4, and 5;

s″ is selected from 0, 1, 2, 3, 4, and 5; and

t is selected from 0, 1, 2, 3, 4, and 5.

39. A method according to claim 33 , wherein:

W 1 is C(═O)NR 15 ;

h is 1;

g is 3;

R 13 and R 14 are independently H;

x is 1;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

40. A method according to claim 33 , wherein:

x is 0;

k is 1;

Z is aryl substituted with 0-3 R 16 ;

g′ is 1;

W 2 is NH;

R 13a and R 14a are independently H;

h′ is 1; and

x′ is 1.

41. A method according to claim 33 , wherein:

W 1 is C(═O)NR 15 ;

h is 1;

g is 2;

R 13 and R 14 are independently H;

x is 1;

k is 0;

g′ is 1;

R 13a and R 14a are independently H; or C 1-5 alkyl substituted with 0-3 R 16 ;

R 16 is SO 3 H;

W 2 is NHC(═O) or NH;

h′ is 1; and

x′ is 2.

42. A method according to claim 33 , wherein:

W 1 is C(═O)NH;

h is 1;

g is 3;

R 13 and R 14 are independently H;

k is 0;

g′ is O;

x is 1;

W 2 is —NH(C═O)— or —(OCH 2 CH 2 ) 76-84 —;

h′ is 2; and

x′ is 1.

43. A method according to claim 33 , wherein:

x is 0;

k is 0;

g′ is 3;

h′ is 1;

W 2 is NH; and

x′ is 1.

44. A method according to claim 33 , wherein

x is 0;

Z is aryl substituted with 0-3 R 16 ;

k is 1;

g′ is 1;

R 13a R 14a are independently H;

W 2 is NHC(═O) or —(OCH 2 CH 2 ) 76-84 —; and

x′ is 1.

45. A method according to claim 33 , wherein:

W 1 is C═O;

g is 2;

R 13 and R 14 are independently H;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

46. A method according to claim 33 , wherein:

h′ is 1;

W 2 is NH; and

x′ is 1.

47. A method according to claim 33 , wherein:

x is 0;

Z is aryl substituted with 0-3 R 16 ;

k is 1;

g′ is 1;

R 13a R 14a are independently H;

W 2 is NHC(═O) or —(OCH 2 CH 2 ) 76-84 —; and

x′ is 1.

48. A method according to claim 33 , wherein:

W 1 is C═O;

g is 2;

R 13 and R 14 are independently H;

k is 0;

g′ is 0;

h′ is 1;

W 2 is NH; and

x′ is 1.

49. A method according to claim 33 , wherein K is a lipid or a compound of the formula:

wherein:

A 9 is OR 32 ;

A 10 is OR 32 ;

R 32 is C(═O)C 1-15 alkyl;

E 9 is C 1-4 alkylene substituted with 1-3 R 33 ;

R 33 is independently selected at each occurrence from the group: R 35 , —PO 3 H—R 35 , ═O, —CO 2 R 34 , —C(═O)R 34 , —CH 2 OR 34 , —OR 34 , and C 1-5 alkyl; and

R 34 is independently selected at each occurrence from the group: R 35 , H, C 1-6 alkyl, phenyl, and benzyl.

50. A method according to claim 33 , wherein K is a compound of the formula:

wherein:

A 1 is a bond to L n ;

E 1 is C 1 alkyl substituted by R 23 ;

A 2 is NH;

E 2 is C 2 alkyl substituted with 0-1R 23 ;

A 3 is —O—P(O)(R 21 )—O—;

E 3 is C 1 alkyl;

A 4 and A 5 are each —O—;

E 4 and E 6 are each independently C 1-16 alkyl substituted with 0-1R 23 ;

E 5 is C 1 alkyl;

A 5 is —O—;

R 21 is —OH; and

R 23 is ═O.

51. A method according to claim 33 , wherein the compound is:

pharmaceutically acceptable salt thereof.

52. A method according to claim 33 , wherein the echogenic gas is a perfluorocarbon gas or sulfur hexafluoride.

53. A method according to claim 52 , wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, and perfluorohexane.

Assignments (15)

RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022

From: WELLS FARGO BANK, N.A.

To: LANTHEUS MEDICAL IMAGING, INC.

Reel/Frame 062047/0925 →

SECURITY AGREEMENT Recorded Jun 28, 2019

From: LANTHEUS MEDICAL IMAGING, INC.

To: WELLS FARGO BANK, N.A.

Reel/Frame 049628/0001 →

RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019

From: JPMORGAN CHASE BANK, N.A.

To: LANTHEUS MEDICAL IMAGING, INC.